ThermoLife International, LLC v. Gaspari Nutrition, Inc.

871 F. Supp. 2d 905, 2012 U.S. Dist. LEXIS 68326, 2012 WL 1752977
CourtDistrict Court, D. Arizona
DecidedMay 16, 2012
DocketNo. CV 11-01056-PHX-NVW
StatusPublished
Cited by4 cases

This text of 871 F. Supp. 2d 905 (ThermoLife International, LLC v. Gaspari Nutrition, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Arizona primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
ThermoLife International, LLC v. Gaspari Nutrition, Inc., 871 F. Supp. 2d 905, 2012 U.S. Dist. LEXIS 68326, 2012 WL 1752977 (D. Ariz. 2012).

Opinion

ORDER

NEIL V. WAKE, District Judge.

Before the Court is Defendant’s Motion to Dismiss Counts 1, 2, 3, 4, 5, 6, 7, 8, 9, and 11 of Plaintiffs First Amended Complaint (Doc. 39). The Motion will be denied in part and granted in part for the reasons stated below.

I. BACKGROUND FACTS

Plaintiff ThermoLife International, LLC (“ThermoLife”) and Defendant Gaspari Nutrition, Inc. (“Gaspari”) are both suppliers of dietary supplements targeted at competiti claims that Gaspari falsely and misleadingly marketed and sold its products — specifically Defendant’s Novedex XT, Halodrol Liquigels, Halodrol MT, and SuperPump 250 products — as safe, natural, complaint with the federal Dietary Supplement Health and Education Act of 1994 (DSHEA), and legal. Plaintiff makes nine separate claims of false advertising related to Defendant’s claims that (1) it only sells legal products; (2) Novedex XT is DSHEA compliant; (3) Novedex XT is naturally occurring; (4) Novedex XT is safe; (5) Halodrol Liquigels and Halodrol MT are DSHEA complaint; (6) Halodrol Liquigels and Halodrol MT are safe; (7) Halodrol Liguigels and Halodrol MT contain 95% 3,4r-divanillytetrahydrofuran; (8) SuperPump 250 contains turkesterone; and (9) SuperPump 250 contains effective doses of turkesterone. In 2010, the FDA issued reports stating that Defendant’s Novedex XT and Halodrol products were not DSHEA compliant. Plaintiff asserts that Defendant’s products contain unsafe materials that are not naturally occurring, even though they were advertised as safe and naturally occurring.

In addition, Plaintiff asserts that it tested material that was marketed and sold as 95% 3,4-divanillytetrahydrofuran and concluded that commercial production of 95% 3,4-divanillytetrahydrofuran was cost prohibitive, and that therefore Defendant’s Halodrol products could not actually contain 95% 3,4-divanillytetrahydrofuran. Plaintiff also asserts that it tested Defendant’s SuperPump 250 product and did not detect the presence of any turkesterone. Even if SuperPump 250 were to contain some small trace of turkesterone, such trace amounts would not be an effective dose. Accordingly, Plaintiff asserts Defendant falsely advertised that the Super-Pump 250 contained effective levels of Turkesterone. Plaintiff cites to various statements made by Defendant and its agents from 2006 until 2010 to support its claims.

Plaintiff manufactures dietary supplements that are in direct competition with Defendant’s products, such as Plaintiffs T-BOL, E-BOL, Tribosten, and Ecdysten products, and that it sells and markets its products through the same stores and channels as Defendant. Plaintiff also claims to be the market leader in the use of turkesterone in dietary supplements and that it has an exclusive distribution agreement with the only company known to produce turkesterone for use in dietary supplements. Plaintiff asserts that it has been harmed by Defendant’s false and misleading advertisements related to these products through a direct diversion of Plaintiffs sales and a lessening of the goodwill associated with its products.

Finally, Plaintiff alleges that Defendant improperly prevented Plaintiff from attending and exhibiting at the 2009 Mr. Olympia Weekend Expo bodybuilding competition and trade show by contacting American Media, Inc., the organizer of the event, and threatening to pull its advertising if ThermoLife was allowed to exhibit at the event. Plaintiff claims Defendant’s ac[908]*908tions caused Plaintiff to lose business opportunities and unrecoupable costs it had expended in anticipation of attending the competition, such as plane tickets, hotel reservations, and planning its exhibition. Plaintiff claims Defendant intentionally and maliciously interfered with its contractual relationship with American Media, Inc., as well as preventing Plaintiff from earning business and goodwill at the event.

On December 16, 2011, 2011 WL 6296833, the Court granted Defendant’s motion to dismiss Plaintiffs original complaint and gave Plaintiff leave to file an amended complaint (Doc. 34), which Plaintiff filed on January 13, 2012 (Doc. 38). Plaintiffs amended complaint raises the above-discussed nine counts for false advertising under 15 U.S.C. § 1125(a)(1)(B) (hereinafter “the Lanham Act”) related to statements made about Defendant’s products, one count for common law unfair competition, and one count for tortious interference with business and business expectancy. Defendant now moves to dismiss the counts for false advertising and tortious interference.

II. LEGAL STANDARD

On a motion to dismiss under Fed. R.Civ.P. 12(b)(6), all allegations of material fact are assumed to be true and construed in the light most favorable to the nonmoving party. Cousins v. Lockyer, 568 F.3d 1063, 1067 (9th Cir.2009). To avoid dismissal, a complaint must contain “only enough facts to state a claim for relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007). “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 129 S.Ct. 1937, 1949, 173 L.Ed.2d 868 (2009). However, the principle that a court accepts as true all of the allegations in a complaint does not apply to legal conclusions or eonelusory factual allegations. Id. at 1949, 1951. “Threadbare recitals of the elements of a cause of action, supported by mere eonelusory statements, do not suffice.” Id. at 1949. “A plaintiffs obligation to provide the grounds of his entitlement to relief requires more than labels and conclusions, and a formulaic recitation of the elements of a cause of action will not do.” Twombly, 550 U.S. at 555, 127 S.Ct. 1955.

III. ANALYSIS

Defendant moves to dismiss Plaintiffs counts for false advertising under the Lanham Act for lack of standing and untimeliness. Defendant also moves to dismiss Plaintiffs count for tortious interference for failing to state sufficient facts to support that claim.

A. Standing Under the Lanham Act

Defendant claims that the first nine counts of Plaintiffs amended complaint fail because Plaintiff has not suffered a commercial injury based on Defendant’s alleged misrepresentations and therefore does not have standing to bring a claim for false advertising under the Lanham Act. In order for a plaintiff to have standing to state a claim under the false advertising provisions of the Lanham Act, the plaintiff must allege “(1) a commercial injury based upon a misrepresentation about a product; and (2) that the injury is ‘competitive,’ or harmful to the plaintiffs ability to compete with the defendant.” TrafficSchool.com, Inc. v. Edriver Inc., 653 F.3d 820, 826 (9th Cir.2011) (quoting Jack Russell Terrier Network of Northern Ca. v. Am. Kennel Club, Inc., 407 F.3d 1027, 1037 (9th Cir.2005)).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
871 F. Supp. 2d 905, 2012 U.S. Dist. LEXIS 68326, 2012 WL 1752977, Counsel Stack Legal Research, https://law.counselstack.com/opinion/thermolife-international-llc-v-gaspari-nutrition-inc-azd-2012.